Evidence map›Paper›PMID 42216156›Full record

ArticleBMC microbiology2026

Contezolid and polymyxin B nonapeptide combination reveals antibacterial synergy against multidrug-resistant Acinetobacter baumannii strains.

Danrui Hao, Yuhang Huang, Tianzhu Zhao, Runyu Wang, Wei Jiang, Xiangting Yuan, Xinrong Wang, Yiwen Chu, Kelei Zhao, Ting Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Danrui Hao *Antibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Yuhang Huang *Antibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Tianzhu Zhao *Affiliated Meishan Hospital of Chengdu University of Traditional Chinese Medicine/Traditional Chinese Medicine Hospital of Meishan, Meishan, 620010, China.
Runyu WangAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Wei JiangAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Xiangting YuanAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Xinrong WangAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Yiwen ChuAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Kelei ZhaoAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Ting HuangAntibiotics Innovation and Resistance Control Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, 610106, China. huangting@cdu.edu.cn.
Zhenxing WangAffiliated Meishan Hospital of Chengdu University of Traditional Chinese Medicine/Traditional Chinese Medicine Hospital of Meishan, Meishan, 620010, China. wangzhenxing@cdutcm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcinetobacter baumannii is a notorious clinical pathogen that predominantly causes nosocomial infections. The multidrug resistant Acinetobacter baumannii clinical isolates are becoming more prevalent on a global scale. In this study, we aimed to determine the potential synergistic antibacterial activity of contezolid in combination with polymyxin B nonapeptide (PBNP) against various A. baumannii strains.

resultsContezolid, a commonly-used agents targeting Gram-positive bacteria, in combination with PBNP (CP) was used to explore the potential synergistic antibacterial activity against A. baumannii in vitro and Caenorhabditis elegans models. We found that CP treatment exhibited a strong synergistic effect on A. baumannii or multidrug resistant A. baumannii. CP also inhibited the biofilm formation and alter morphology of A. baumannii compared to the control group. Moreover, the residual bacteria were significantly decreased in the CP-treated murine alveolar macrophages (MH-S). Importantly, CP treatment improved the survival of C. elegans compared to the control or monotherapy group.

conclusionsThis strategy improved antibacterial activity spectrum of agents targeting Gram-positive bacteria like contezolid. Nevertheless, CP combination therapy requires further validation in mammalian infection models.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialPolymyxin BAcinetobacter InfectionsAnimalsBiofilmsCaenorhabditis elegansDrug SynergismMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsPolymyxin Bpolymyxin B nonapeptideAcinetobacter baumanniiAntibacterial activityContezolidPolymyxin B nonapeptideSynergism

Identifiers

PMID42216156
PMCPMC13422302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.